Bhi Sinus Tablet
FDA Label NDC 62795-1017

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Medinatura Inc for the product Bhi Sinus (NDC 62795-1017). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding active ingredients, inactive ingredients, purpose, uses, directions, warnings, keep out of reach of children, bhi sinus tablet, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Active Ingredients

Each tablet contains: *Euphorbium officinarum 6X, *Hydrastis canadensis 6X, Kali bichromicum 6X, Kali iodatum 8X, *Phosphorus 8X, *Pulsatilla 4X, *Thuja occidentalis 6X 42.9 mg each.

*Natural Ingredients

Inactive Ingredients

Lactose and Magnesium stearate

Purpose

Sinus Relief Tablets

Relieves:

• Nasal Congestion

• Sinus Headache & Pressure

• Cold/Flu Nasal Symptoms

Uses

For the temporary relief of minor sinus congestion and pressure due to allergic rhinitis and colds

Directions

At first sign of symptoms: Adults and children 4 years and older: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Do not exceed 12 tablets in 24 hours.

Standard dosage: Adults and children 4 years and older: 3 tablets per day, taking 1 tablet every 4 to 6 hours. For children under 4, consult your health professional.

Allow tablets to dissolve completely in the mouth, do not swallow.

Warnings

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If symptoms persist or worsen, a health professional should be consulted. Do not use if known sensitivity to BHI Sinus or any of its ingredients exists.

Keep Out Of Reach Of Children

Keep out of reach of children.

* Please review the disclaimer below.